Global Male Infertility Diagnosis and Treatment Market Research and Analysis, 2015-2022
MARKET INSIGHTS
The global male infertility market is anticipated to grow with the CAGR of 5.2% during the period 2017-2022. The major factors that are augmenting the growth of the market are estimated to be increasing alcohol consumption, increasing age, rising environmental pollution etc. Additionally, increasing stress, changing life style, increasing infertility rate and medication affecting genetic abnormalities and Spermatogenesis are also major factors that are fueling the male infertility market across the globe.
Alcohol consumption is estimated to be one of the major factors that is fueling the growth of the male infertility market across the globe. According to National Survey on Drug Use and Health (NSDUH), In 2015, approximately 80% of the population aging 18 or older drank alcohol. About 27% of the population aging between 18 or older are engaged in binge drinking, while more than 6% of the population reported that they are engaged in heavy drinking. Heavy alcohol consumption affects the fertility of male. Therefore it is estimated that the increasing alcohol consumption is going to augment the growth of the male infertility diagnosis and treatment market across the globe.
However, there are certain factors that are affecting the growth of the market. High cost infertility treatment, low accuracy rate of the treatment and social stigma related to the infertility treatment are the major factors constraints that are hindering the growth of the global male infertility market across the globe. It is estimated that out of 40% fertile male the only 15% male choose infertility treatment rest don’t opt for treatment due to high cost of treatment, guilt, embarrassment and other reasons etc.
GEOGRAPHICAL INSIGHTS
Global male infertility is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of the geography, market is bifurcated into North America, Europe, Asia Pacific and Rest of the World. North America is accounted to be the highest revenue generating region in the global male infertility market owing to more awareness and high alcohol consumption in the region. Furthermore, increasing incidences of infertility in the region is also one of the major factors backing the growth of the market. In the year 2015, it is estimated that, about 15% of the couples in North America were infertile. These are the major factors driving the growth of the market in the region.Asia Pacific is estimated to be the fastest growing region in the male infertility market. Increasing medical tourism in the countries like Thailand and India are driving the growth of the market.
COMPETITIVE INSIGHTS
Key players of the male infertility diagnosis and treatment market are Access Pharmaceuticals INC., Andrology Solutions, Aska Pharmaceuticals INC, Bayer AG, Bristol-Mayers Squibb Co, Cadila Healthcare LTD, Church & Dwight Company INC, Cook Medical INC, Coopersurgical INC, Cordex Pharma INC, Eli Lilly & Co. and so on. In order to survive in the market these players adopt different strategies such as merger, acquisition, product launch, geographical expansion and so on. For Example: In 2016, Bayer AG acquired Monsanto a US based company in a $66 billion deal.
MARKET SEGMENTATION
1. GLOBAL MALE INFERTILITY MARKET BY DIAGNOSIS
1.1. SEMEN ANALYSIS MARKET
1.2. GENETIC TESTING MARKET
1.3. TESTICULAR BIOPSY MARKET
1.4. HORMONE TESTING MARKET
1.5. OTHERS
2. GLOBAL MALE INFERTILITY MARKET BY TREATMENT
2.1. DRUGS AND MEDICINES MARKET
2.2. SURGICAL MARKET
2.3. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
2.4. OTHERS
OMR REPORT COVERS:
The global male infertility market is anticipated to grow with the CAGR of 5.2% during the period 2017-2022. The major factors that are augmenting the growth of the market are estimated to be increasing alcohol consumption, increasing age, rising environmental pollution etc. Additionally, increasing stress, changing life style, increasing infertility rate and medication affecting genetic abnormalities and Spermatogenesis are also major factors that are fueling the male infertility market across the globe.
Alcohol consumption is estimated to be one of the major factors that is fueling the growth of the male infertility market across the globe. According to National Survey on Drug Use and Health (NSDUH), In 2015, approximately 80% of the population aging 18 or older drank alcohol. About 27% of the population aging between 18 or older are engaged in binge drinking, while more than 6% of the population reported that they are engaged in heavy drinking. Heavy alcohol consumption affects the fertility of male. Therefore it is estimated that the increasing alcohol consumption is going to augment the growth of the male infertility diagnosis and treatment market across the globe.
However, there are certain factors that are affecting the growth of the market. High cost infertility treatment, low accuracy rate of the treatment and social stigma related to the infertility treatment are the major factors constraints that are hindering the growth of the global male infertility market across the globe. It is estimated that out of 40% fertile male the only 15% male choose infertility treatment rest don’t opt for treatment due to high cost of treatment, guilt, embarrassment and other reasons etc.
GEOGRAPHICAL INSIGHTS
Global male infertility is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of the geography, market is bifurcated into North America, Europe, Asia Pacific and Rest of the World. North America is accounted to be the highest revenue generating region in the global male infertility market owing to more awareness and high alcohol consumption in the region. Furthermore, increasing incidences of infertility in the region is also one of the major factors backing the growth of the market. In the year 2015, it is estimated that, about 15% of the couples in North America were infertile. These are the major factors driving the growth of the market in the region.Asia Pacific is estimated to be the fastest growing region in the male infertility market. Increasing medical tourism in the countries like Thailand and India are driving the growth of the market.
COMPETITIVE INSIGHTS
Key players of the male infertility diagnosis and treatment market are Access Pharmaceuticals INC., Andrology Solutions, Aska Pharmaceuticals INC, Bayer AG, Bristol-Mayers Squibb Co, Cadila Healthcare LTD, Church & Dwight Company INC, Cook Medical INC, Coopersurgical INC, Cordex Pharma INC, Eli Lilly & Co. and so on. In order to survive in the market these players adopt different strategies such as merger, acquisition, product launch, geographical expansion and so on. For Example: In 2016, Bayer AG acquired Monsanto a US based company in a $66 billion deal.
MARKET SEGMENTATION
1. GLOBAL MALE INFERTILITY MARKET BY DIAGNOSIS
1.1. SEMEN ANALYSIS MARKET
1.2. GENETIC TESTING MARKET
1.3. TESTICULAR BIOPSY MARKET
1.4. HORMONE TESTING MARKET
1.5. OTHERS
2. GLOBAL MALE INFERTILITY MARKET BY TREATMENT
2.1. DRUGS AND MEDICINES MARKET
2.2. SURGICAL MARKET
2.3. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
2.4. OTHERS
OMR REPORT COVERS:
- Comprehensive research methodology of Global Male Infertility Market
- This report also includes detailed and extensive market overview with Analyst insights & key market trends.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Male Infertility Market
- Insights about market determinants which are stimulating the Global Male Infertility Market
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. CHANGING LIFE STYLE
3.1.2. RISING ENVIRONMENTAL POLLUTION
3.1.3. INCREASING AGE
3.1.4. MEDICATION AFFECTING GENETIC ABNORMALITIES AND SPERMATOGENESIS
3.1.5. INCREASING ALCOHOL CONSUMPTION
3.1.6. GROWING INFERTILITY RATE
3.2. RESTRAINTS
3.2.1. HIGH COST OF TREATMENT
3.2.2. INCREASING INCIDENCES OF TREATMENT FAILURES
3.2.3. SOCIAL STIGMA RELATED TO INFERTILITY TREATMENT
3.3. OPPORTUNITIES
3.3.1. INCREASING MEDICAL TOURISM
3.3.2. INCREASING AWARENESS AMONG PEOPLE
4. MARKET SEGMENTATION
4.1. GLOBAL MALE INFERTILITY MARKET BY DIAGNOSIS
4.1.1. SEMEN ANALYSIS MARKET
4.1.2. GENETIC TESTING MARKET
4.1.3. TESTICULAR BIOPSY MARKET
4.1.4. HORMONE TESTING MARKET
4.1.5. OTHERS
4.2. GLOBAL MALE INFERTILITY MARKET BY TREATMENT
4.2.1. DRUGS AND MEDICINES MARKET
4.2.2. SURGICAL MARKET
4.2.3. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
4.2.4. OTHERS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ACCESS PHARMACEUTICALS, INC.
7.1.1. INTRODUCTION
7.1.2. ACCESS PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
7.1.3. ACCESS PHARMACEUTICALS, INC. RECENT ACTIVITIES
7.2. ANDROLOGY SOLUTIONS
7.2.1. INTRODUCTION
7.2.2. ANDROLOGY SOLUTIONS PRODUCT PORTFOLIO
7.2.3. ANDROLOGY SOLUTIONS RECENT ACTIVITIES
7.3. ASKA PHARMACEUTICALS, INC.
7.3.1. INTRODUCTION
7.3.2. ASKA PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
7.3.3. ASKA PHARMACEUTICALS, INC. RECENT ACTIVITIES
7.4. BAYER AG
7.4.1. INTRODUCTION
7.4.2. BAYER AG PRODUCT PORTFOLIO
7.4.3. BAYER AG RECENT ACTIVITIES
7.5. BRISTOL-MAYERS SQUIBB CO.
7.5.1. INTRODUCTION
7.5.2. BRISTOL-MAYERS SQUIBB CO. PRODUCT PORTFOLIO
7.5.3. BRISTOL-MAYERS SQUIBB CO.RECENT ACTIVITIES
7.6. CADILA HEALTHCARE LTD.
7.6.1. INTRODUCTION
7.6.2. CADILA HEALTHCARE LTD. PRODUCT PORTFOLIO
7.6.3. CADILA HEALTHCARE LTD. RECENT ACTIVITIES
7.7. CHURCH & DWIGHT COMPANY INC.
7.7.1. INTRODUCTION
7.7.2. CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
7.7.3. CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
7.8. COOK MEDICAL INC.
7.8.1. INTRODUCTION
7.8.2. COOK MEDICAL INC. PRODUCT PORTFOLIO
7.8.3. COOK MEDICAL INC. RECENT ACTIVITIES
7.9. COOPER SURGICAL INC.
7.9.1. INTRODUCTION
7.9.2. COOPER SURGICAL INC. PRODUCT PORTFOLIO
7.9.3. COOPER SURGICAL INC. RECENT ACTIVITIES
7.10. CORDEX PHARMA, INC.
7.10.1. INTRODUCTION
7.10.2. CORDEX PHARMA, INC. PRODUCT PORTFOLIO
7.10.3. CORDEX PHARMA, INC. RECENT ACTIVITIES
7.11. ELI LILLY & CO.
7.11.1. INTRODUCTION
7.11.2. ELI LILLY & CO. PRODUCT PORTFOLIO
7.11.3. ELI LILLY & CO. RECENT ACTIVITIES
7.12. EMD SERONO, INC.
7.12.1. INTRODUCTION
7.12.2. EMD SERONO, INC. PRODUCT PORTFOLIO
7.12.3. EMD SERONO, INC. RECENT ACTIVITIES
7.13. ENDO PHARMACEUTICALS
7.13.1. INTRODUCTION
7.13.2. ENDO PHARMACEUTICALS PRODUCT PORTFOLIO
7.13.3. ENDO PHARMACEUTICALS RECENT ACTIVITIES
7.14. HALOTECH DNA SL
7.14.1. INTRODUCTION
7.14.2. HALOTECH DNA SL PRODUCT PORTFOLIO
7.14.3. HALOTECH DNA SL RECENT ACTIVITIES
7.15. INTAS PHARMACEUTICALS.
7.15.1. INTRODUCTION
7.15.2. INTAS PHARMACEUTICALS PRODUCT PORTFOLIO
7.15.3. INTAS PHARMACEUTICALS RECENT ACTIVITIES
7.16. IRAVINE SCIENTIFIC
7.16.1. INTRODUCTION
7.16.2. IRAVINE SCIENTIFIC PRODUCT PORTFOLIO
7.16.3. IRAVINE SCIENTIFIC RECENT ACTIVITIES
7.17. MERCK SERONO INC.
7.17.1. INTRODUCTION
7.17.2. MERCK SERONO INC. PRODUCT PORTFOLIO
7.17.3. MERCK SERONO INC. RECENT ACTIVITIES
7.18. MICROM UK LTD.
7.18.1. INTRODUCTION
7.18.2. MICROM UK LTD. PRODUCT PORTFOLIO
7.18.3. MICROM UK LTD. RECENT ACTIVITIES
7.19. PANTARHEI BIOSCIENCE B.V.
7.19.1. INTRODUCTION
7.19.2. PANTARHEI BIOSCIENCE B.V. PRODUCT PORTFOLIO
7.19.3. PANTARHEI BIOSCIENCE B.V. RECENT ACTIVITIES
7.20. PARALLABS
7.20.1. INTRODUCTION
7.20.2. PARALLABS PRODUCT PORTFOLIO
7.20.3. PARALLABS RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. CHANGING LIFE STYLE
3.1.2. RISING ENVIRONMENTAL POLLUTION
3.1.3. INCREASING AGE
3.1.4. MEDICATION AFFECTING GENETIC ABNORMALITIES AND SPERMATOGENESIS
3.1.5. INCREASING ALCOHOL CONSUMPTION
3.1.6. GROWING INFERTILITY RATE
3.2. RESTRAINTS
3.2.1. HIGH COST OF TREATMENT
3.2.2. INCREASING INCIDENCES OF TREATMENT FAILURES
3.2.3. SOCIAL STIGMA RELATED TO INFERTILITY TREATMENT
3.3. OPPORTUNITIES
3.3.1. INCREASING MEDICAL TOURISM
3.3.2. INCREASING AWARENESS AMONG PEOPLE
4. MARKET SEGMENTATION
4.1. GLOBAL MALE INFERTILITY MARKET BY DIAGNOSIS
4.1.1. SEMEN ANALYSIS MARKET
4.1.2. GENETIC TESTING MARKET
4.1.3. TESTICULAR BIOPSY MARKET
4.1.4. HORMONE TESTING MARKET
4.1.5. OTHERS
4.2. GLOBAL MALE INFERTILITY MARKET BY TREATMENT
4.2.1. DRUGS AND MEDICINES MARKET
4.2.2. SURGICAL MARKET
4.2.3. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
4.2.4. OTHERS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ACCESS PHARMACEUTICALS, INC.
7.1.1. INTRODUCTION
7.1.2. ACCESS PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
7.1.3. ACCESS PHARMACEUTICALS, INC. RECENT ACTIVITIES
7.2. ANDROLOGY SOLUTIONS
7.2.1. INTRODUCTION
7.2.2. ANDROLOGY SOLUTIONS PRODUCT PORTFOLIO
7.2.3. ANDROLOGY SOLUTIONS RECENT ACTIVITIES
7.3. ASKA PHARMACEUTICALS, INC.
7.3.1. INTRODUCTION
7.3.2. ASKA PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
7.3.3. ASKA PHARMACEUTICALS, INC. RECENT ACTIVITIES
7.4. BAYER AG
7.4.1. INTRODUCTION
7.4.2. BAYER AG PRODUCT PORTFOLIO
7.4.3. BAYER AG RECENT ACTIVITIES
7.5. BRISTOL-MAYERS SQUIBB CO.
7.5.1. INTRODUCTION
7.5.2. BRISTOL-MAYERS SQUIBB CO. PRODUCT PORTFOLIO
7.5.3. BRISTOL-MAYERS SQUIBB CO.RECENT ACTIVITIES
7.6. CADILA HEALTHCARE LTD.
7.6.1. INTRODUCTION
7.6.2. CADILA HEALTHCARE LTD. PRODUCT PORTFOLIO
7.6.3. CADILA HEALTHCARE LTD. RECENT ACTIVITIES
7.7. CHURCH & DWIGHT COMPANY INC.
7.7.1. INTRODUCTION
7.7.2. CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
7.7.3. CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
7.8. COOK MEDICAL INC.
7.8.1. INTRODUCTION
7.8.2. COOK MEDICAL INC. PRODUCT PORTFOLIO
7.8.3. COOK MEDICAL INC. RECENT ACTIVITIES
7.9. COOPER SURGICAL INC.
7.9.1. INTRODUCTION
7.9.2. COOPER SURGICAL INC. PRODUCT PORTFOLIO
7.9.3. COOPER SURGICAL INC. RECENT ACTIVITIES
7.10. CORDEX PHARMA, INC.
7.10.1. INTRODUCTION
7.10.2. CORDEX PHARMA, INC. PRODUCT PORTFOLIO
7.10.3. CORDEX PHARMA, INC. RECENT ACTIVITIES
7.11. ELI LILLY & CO.
7.11.1. INTRODUCTION
7.11.2. ELI LILLY & CO. PRODUCT PORTFOLIO
7.11.3. ELI LILLY & CO. RECENT ACTIVITIES
7.12. EMD SERONO, INC.
7.12.1. INTRODUCTION
7.12.2. EMD SERONO, INC. PRODUCT PORTFOLIO
7.12.3. EMD SERONO, INC. RECENT ACTIVITIES
7.13. ENDO PHARMACEUTICALS
7.13.1. INTRODUCTION
7.13.2. ENDO PHARMACEUTICALS PRODUCT PORTFOLIO
7.13.3. ENDO PHARMACEUTICALS RECENT ACTIVITIES
7.14. HALOTECH DNA SL
7.14.1. INTRODUCTION
7.14.2. HALOTECH DNA SL PRODUCT PORTFOLIO
7.14.3. HALOTECH DNA SL RECENT ACTIVITIES
7.15. INTAS PHARMACEUTICALS.
7.15.1. INTRODUCTION
7.15.2. INTAS PHARMACEUTICALS PRODUCT PORTFOLIO
7.15.3. INTAS PHARMACEUTICALS RECENT ACTIVITIES
7.16. IRAVINE SCIENTIFIC
7.16.1. INTRODUCTION
7.16.2. IRAVINE SCIENTIFIC PRODUCT PORTFOLIO
7.16.3. IRAVINE SCIENTIFIC RECENT ACTIVITIES
7.17. MERCK SERONO INC.
7.17.1. INTRODUCTION
7.17.2. MERCK SERONO INC. PRODUCT PORTFOLIO
7.17.3. MERCK SERONO INC. RECENT ACTIVITIES
7.18. MICROM UK LTD.
7.18.1. INTRODUCTION
7.18.2. MICROM UK LTD. PRODUCT PORTFOLIO
7.18.3. MICROM UK LTD. RECENT ACTIVITIES
7.19. PANTARHEI BIOSCIENCE B.V.
7.19.1. INTRODUCTION
7.19.2. PANTARHEI BIOSCIENCE B.V. PRODUCT PORTFOLIO
7.19.3. PANTARHEI BIOSCIENCE B.V. RECENT ACTIVITIES
7.20. PARALLABS
7.20.1. INTRODUCTION
7.20.2. PARALLABS PRODUCT PORTFOLIO
7.20.3. PARALLABS RECENT ACTIVITIES
LIST OF TABLES
TABLE #1GLOBAL MALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY DIAGNOSIS 2015-2022 ($ MILLION)
TABLE #2GLOBAL SEMEN ANALYSIS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #3GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #4GLOBAL TESTICULAR BIOPSY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #5GLOBAL HORMONE TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #6GLOBAL OTHER TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #7GLOBAL MALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY TREATMENT 2015-2022 ($ MILLION)
TABLE #8GLOBAL DRUG & MEDICINES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #9GLOBAL SURGICAL MARKET RESEARCH AND ANALYSIS, BY CONNECTOR, 2015-2022 ($ MILLION)
TABLE #10GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #11GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #12ACCESS PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
TABLE #13ACCESS PHARMACEUTICALS, INC. RECENT ACTIVITIES
TABLE #14ANDROLOGY SOLUTIONS PRODUCT PORTFOLIO
TABLE #15ANDROLOGY SOLUTIONS RECENT ACTIVITIES
TABLE #16ASKA PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
TABLE #17ASKA PHARMACEUTICALS, INC. RECENT ACTIVITIES
TABLE #18BAYER AG PRODUCT PORTFOLIO
TABLE #19BAYER AG RECENT ACTIVITIES
TABLE #20BRISTOL-MAYERS SQUIBB CO. PRODUCT PORTFOLIO
TABLE #21BRISTOL-MAYERS SQUIBB CO.RECENT ACTIVITIES
TABLE #22CADILA HEALTHCARE LTD. PRODUCT PORTFOLIO
TABLE #23CADILA HEALTHCARE LTD. RECENT ACTIVITIES
TABLE #24CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
TABLE #25CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
TABLE #26COOK MEDICAL INC. PRODUCT PORTFOLIO
TABLE #27COOK MEDICAL INC. RECENT ACTIVITIES
TABLE #28COOPER SURGICAL INC. PRODUCT PORTFOLIO
TABLE #29COOPER SURGICAL INC. RECENT ACTIVITIES
TABLE #30CORDEX PHARMA, INC. PRODUCT PORTFOLIO
TABLE #31CORDEX PHARMA, INC. RECENT ACTIVITIES
TABLE #32ELI LILLY & CO. PRODUCT PORTFOLIO
TABLE #33ELI LILLY & CO. RECENT ACTIVITIES
TABLE #347.12.EMD SERONO, INC.
TABLE #357.12.1.INTRODUCTION
TABLE #36EMD SERONO, INC. PRODUCT PORTFOLIO
TABLE #37EMD SERONO, INC. RECENT ACTIVITIES
TABLE #38ENDO PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #39ENDO PHARMACEUTICALS RECENT ACTIVITIES
TABLE #40HALOTECH DNA SL PRODUCT PORTFOLIO
TABLE #41HALOTECH DNA SL RECENT ACTIVITIES
TABLE #42INTAS PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #43INTAS PHARMACEUTICALS RECENT ACTIVITIES
TABLE #44IRAVINE SCIENTIFIC PRODUCT PORTFOLIO
TABLE #45IRAVINE SCIENTIFIC RECENT ACTIVITIES
TABLE #46MERCK SERONO INC. PRODUCT PORTFOLIO
TABLE #47MERCK SERONO INC. RECENT ACTIVITIES
TABLE #48MICROM UK LTD. PRODUCT PORTFOLIO
TABLE #49MICROM UK LTD. RECENT ACTIVITIES
TABLE #50PANTARHEI BIOSCIENCE B.V. PRODUCT PORTFOLIO
TABLE #51PANTARHEI BIOSCIENCE B.V. RECENT ACTIVITIES
TABLE #52PARALLABS PRODUCT PORTFOLIO
TABLE #53PARALLABS RECENT ACTIVITIES
TABLE #1GLOBAL MALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY DIAGNOSIS 2015-2022 ($ MILLION)
TABLE #2GLOBAL SEMEN ANALYSIS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #3GLOBAL GENETIC TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #4GLOBAL TESTICULAR BIOPSY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #5GLOBAL HORMONE TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #6GLOBAL OTHER TESTING MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #7GLOBAL MALE INFERTILITY DIAGNOSIS AND TREATMENT market RESEARCH AND ANALYSIS, BY TREATMENT 2015-2022 ($ MILLION)
TABLE #8GLOBAL DRUG & MEDICINES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #9GLOBAL SURGICAL MARKET RESEARCH AND ANALYSIS, BY CONNECTOR, 2015-2022 ($ MILLION)
TABLE #10GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #11GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
TABLE #12ACCESS PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
TABLE #13ACCESS PHARMACEUTICALS, INC. RECENT ACTIVITIES
TABLE #14ANDROLOGY SOLUTIONS PRODUCT PORTFOLIO
TABLE #15ANDROLOGY SOLUTIONS RECENT ACTIVITIES
TABLE #16ASKA PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
TABLE #17ASKA PHARMACEUTICALS, INC. RECENT ACTIVITIES
TABLE #18BAYER AG PRODUCT PORTFOLIO
TABLE #19BAYER AG RECENT ACTIVITIES
TABLE #20BRISTOL-MAYERS SQUIBB CO. PRODUCT PORTFOLIO
TABLE #21BRISTOL-MAYERS SQUIBB CO.RECENT ACTIVITIES
TABLE #22CADILA HEALTHCARE LTD. PRODUCT PORTFOLIO
TABLE #23CADILA HEALTHCARE LTD. RECENT ACTIVITIES
TABLE #24CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
TABLE #25CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
TABLE #26COOK MEDICAL INC. PRODUCT PORTFOLIO
TABLE #27COOK MEDICAL INC. RECENT ACTIVITIES
TABLE #28COOPER SURGICAL INC. PRODUCT PORTFOLIO
TABLE #29COOPER SURGICAL INC. RECENT ACTIVITIES
TABLE #30CORDEX PHARMA, INC. PRODUCT PORTFOLIO
TABLE #31CORDEX PHARMA, INC. RECENT ACTIVITIES
TABLE #32ELI LILLY & CO. PRODUCT PORTFOLIO
TABLE #33ELI LILLY & CO. RECENT ACTIVITIES
TABLE #347.12.EMD SERONO, INC.
TABLE #357.12.1.INTRODUCTION
TABLE #36EMD SERONO, INC. PRODUCT PORTFOLIO
TABLE #37EMD SERONO, INC. RECENT ACTIVITIES
TABLE #38ENDO PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #39ENDO PHARMACEUTICALS RECENT ACTIVITIES
TABLE #40HALOTECH DNA SL PRODUCT PORTFOLIO
TABLE #41HALOTECH DNA SL RECENT ACTIVITIES
TABLE #42INTAS PHARMACEUTICALS PRODUCT PORTFOLIO
TABLE #43INTAS PHARMACEUTICALS RECENT ACTIVITIES
TABLE #44IRAVINE SCIENTIFIC PRODUCT PORTFOLIO
TABLE #45IRAVINE SCIENTIFIC RECENT ACTIVITIES
TABLE #46MERCK SERONO INC. PRODUCT PORTFOLIO
TABLE #47MERCK SERONO INC. RECENT ACTIVITIES
TABLE #48MICROM UK LTD. PRODUCT PORTFOLIO
TABLE #49MICROM UK LTD. RECENT ACTIVITIES
TABLE #50PANTARHEI BIOSCIENCE B.V. PRODUCT PORTFOLIO
TABLE #51PANTARHEI BIOSCIENCE B.V. RECENT ACTIVITIES
TABLE #52PARALLABS PRODUCT PORTFOLIO
TABLE #53PARALLABS RECENT ACTIVITIES
LIST OF FIGURES
FIGURE #1NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #2US MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #3CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #4EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #5UK MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #6FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #7GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #8ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #9SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #10ROE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #11ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #12INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #13CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #14JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #15ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #16REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022
COMPANIES MENTIONED
1. ACCESS PHARMACEUTICALS, INC.
2. andrology solutions
3. Aska Pharmaceuticals, INC.
4. Bayer AG
5. Bristol-Mayers squibb co.
6. Cadila Healthcare LTD.
7. Church & Dwight Company Inc.
8. Cook medical inc.
9. Coopersurgical Inc.
10. Cordex Pharma, INC.
11. Eli lilly & co.
12. EMD Serono, INC.
13. Endo Pharamceuticals
14. halotech DNA SL
15. Intas Pharmaceuticals
16. Iravine Sceintific
17. Merck serono INC.
18. microm UK LTD.
19. Pantarhei Bioscience B.V.
20. parallabs
21. SCSA diagnositcs, inc.
FIGURE #1NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #2US MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #3CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #4EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #5UK MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #6FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #7GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #8ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #9SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #10ROE MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #11ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #12INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #13CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #14JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #15ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022
FIGURE #16REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022
COMPANIES MENTIONED
1. ACCESS PHARMACEUTICALS, INC.
2. andrology solutions
3. Aska Pharmaceuticals, INC.
4. Bayer AG
5. Bristol-Mayers squibb co.
6. Cadila Healthcare LTD.
7. Church & Dwight Company Inc.
8. Cook medical inc.
9. Coopersurgical Inc.
10. Cordex Pharma, INC.
11. Eli lilly & co.
12. EMD Serono, INC.
13. Endo Pharamceuticals
14. halotech DNA SL
15. Intas Pharmaceuticals
16. Iravine Sceintific
17. Merck serono INC.
18. microm UK LTD.
19. Pantarhei Bioscience B.V.
20. parallabs
21. SCSA diagnositcs, inc.
